The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1596
April 20, 2020
View Complete Issue         Table of Contents 2019 
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
April 20, 2020 (Issue: 1596)
The FDA has approved nasal spray formulations of the benzodiazepines diazepam (Valtoco — Neurelis) and midazolam (Nayzilam — UCB) for acute treatment of intermittent episodes of frequent seizure activity (seizure clusters). Diazepam rectal...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
Article code: 1596b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.